Efficacy and Safety of Multihole Partially Covered Self-Expandable Metal Stents for Distal Malignant Biliary Obstruction: A Single-Center Retrospective Study
{"title":"Efficacy and Safety of Multihole Partially Covered Self-Expandable Metal Stents for Distal Malignant Biliary Obstruction: A Single-Center Retrospective Study","authors":"Kengo Matsumoto, Kazuhide Iwasa, Asuka Watanabe, Hiroki Takiyama, Satoru Okabe, Naoto Osugi, Dai Nakamatsu, Masashi Yamamoto, Shiro Hayashi, Koji Fukui, Tsutomu Nishida","doi":"10.1002/deo2.70168","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Covered self-expandable metal stents (SEMS) are the standard for managing unresectable distal malignant biliary obstruction (DMBO), as they prolong the time to recurrent biliary obstruction (TRBO). However, fully covered SEMS (FCSEMS) increases the risk of cholecystitis and pancreatitis. This exploratory study evaluated a novel multihole partially covered SEMS (MHSEMS) designed to reduce these risks.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The clinical data of 26 DMBO patients treated with MHSEMSs were retrospectively compared with those of 63 patients treated with FCSEMSs between April 2018 and October 2024. The outcomes included clinical success, early complications, and recurrent biliary obstruction (RBO).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The baseline characteristics, including age (median 78 years), sex distribution (55.2% vs. 57.7% male), BMI (20.5 vs. 19.8), tumor size (27 mm vs. 30 mm), and stricture length (20 mm vs. 19.5 mm), were comparable between the groups. Procedural factors, including initial papillary cannulation (34.9% vs. 26.9%) and pancreatography (12.9% vs. 15.4%), were also similar in terms of incidence. Early complications were less common in the MHSEMS group (7.7% vs. 23.8%), with no cases of cholecystitis observed. Fewer early complications were observed with MHSEMS, suggesting potential clinical benefits. The RBO rates (7.7% vs. 15.9%, <i>p</i> = 0.28) and median TRBO (151 vs. 141.5 days, <i>p</i> = 0.87) were also comparable.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Although the differences in outcomes were not statistically significant, the incidence of early complications was lower, especially for cholecystitis, with the MHSEMS in the management of DMBO. Larger prospective studies are needed to confirm these preliminary findings.</p>\n </section>\n </div>","PeriodicalId":93973,"journal":{"name":"DEN open","volume":"6 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/deo2.70168","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DEN open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/deo2.70168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Covered self-expandable metal stents (SEMS) are the standard for managing unresectable distal malignant biliary obstruction (DMBO), as they prolong the time to recurrent biliary obstruction (TRBO). However, fully covered SEMS (FCSEMS) increases the risk of cholecystitis and pancreatitis. This exploratory study evaluated a novel multihole partially covered SEMS (MHSEMS) designed to reduce these risks.
Methods
The clinical data of 26 DMBO patients treated with MHSEMSs were retrospectively compared with those of 63 patients treated with FCSEMSs between April 2018 and October 2024. The outcomes included clinical success, early complications, and recurrent biliary obstruction (RBO).
Results
The baseline characteristics, including age (median 78 years), sex distribution (55.2% vs. 57.7% male), BMI (20.5 vs. 19.8), tumor size (27 mm vs. 30 mm), and stricture length (20 mm vs. 19.5 mm), were comparable between the groups. Procedural factors, including initial papillary cannulation (34.9% vs. 26.9%) and pancreatography (12.9% vs. 15.4%), were also similar in terms of incidence. Early complications were less common in the MHSEMS group (7.7% vs. 23.8%), with no cases of cholecystitis observed. Fewer early complications were observed with MHSEMS, suggesting potential clinical benefits. The RBO rates (7.7% vs. 15.9%, p = 0.28) and median TRBO (151 vs. 141.5 days, p = 0.87) were also comparable.
Conclusion
Although the differences in outcomes were not statistically significant, the incidence of early complications was lower, especially for cholecystitis, with the MHSEMS in the management of DMBO. Larger prospective studies are needed to confirm these preliminary findings.
有盖自膨胀金属支架(SEMS)是治疗不可切除的远端恶性胆道梗阻(DMBO)的标准,因为它们延长了复发性胆道梗阻(TRBO)的时间。然而,完全覆盖的SEMS (fcems)增加了胆囊炎和胰腺炎的风险。这项探索性研究评估了一种新型的多孔部分覆盖式SEMS (mshsems),旨在降低这些风险。方法回顾性分析2018年4月至2024年10月26例采用MHSEMSs治疗的DMBO患者的临床资料,并与63例采用FCSEMSs治疗的患者进行比较。结果包括临床成功、早期并发症和复发性胆道梗阻(RBO)。结果基线特征,包括年龄(中位78岁)、性别分布(55.2%对57.7%男性)、BMI(20.5对19.8)、肿瘤大小(27mm对30mm)和狭窄长度(20mm对19.5 mm),组间具有可比性。手术因素,包括初始乳头状插管(34.9% vs. 26.9%)和胰腺造影(12.9% vs. 15.4%),在发病率方面也相似。MHSEMS组早期并发症较少见(7.7% vs. 23.8%),无胆囊炎病例。MHSEMS的早期并发症较少,提示潜在的临床益处。RBO率(7.7% vs 15.9%, p = 0.28)和中位TRBO (151 vs 141.5天,p = 0.87)也具有可比性。结论虽然结果差异无统计学意义,但MHSEMS治疗DMBO的早期并发症发生率较低,尤其是胆囊炎。需要更大规模的前瞻性研究来证实这些初步发现。